COVID-19

A Novel Broad-Spectrum Antiviral with Activity Against RSV

Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE /…

2 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…

2 months ago

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an…

2 months ago

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan

– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training…

2 months ago

MiNK Reports First Quarter 2024 Results

Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American…

2 months ago

Strawberry Fields REIT Announces First Quarter 2024 Operating Results

South Bend, Indiana--(Newsfile Corp. - May 14, 2024) - Strawberry Fields REIT, Inc. (NYSE American: STRW) (the "Company") reported today…

2 months ago

Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the…

2 months ago

Ainos Reports First Quarter 2024 Financial Results

Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for…

2 months ago

Moderna to Present at Upcoming Conferences in May/June 2024

CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming…

2 months ago

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update

-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a…

2 months ago